Viva Biotech Holdings (VB0) — Capital Reinvestment Ratio

Latest as of June 2023: 0.32x

Viva Biotech Holdings (VB0) has a Capital Reinvestment Ratio of 0.32x as of June 2023, meaning it reinvests 0% of its operating cash flow (€158.72 Million) in capital expenditures (€50.80 Million). See Viva Biotech Holdings net asset quality index to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.32x
Capex / Operating Cash Flow

Operating Cash Flow

€158.72 Million
EUR

Capital Expenditures

€50.80 Million
EUR

Data as of

Jun 2023
Most recent filing

Viva Biotech Holdings Capital Reinvestment Ratio (2016–2024)

This chart tracks Viva Biotech Holdings's Capital Reinvestment Ratio across 9 annual periods. Check Viva Biotech Holdings investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Viva Biotech Holdings (2016–2024)

Year-by-year Capital Reinvestment Ratio for Viva Biotech Holdings from 2016 to 2024. For live market cap and broader valuation context, see VB0 market cap.

Year Reinvestment Ratio Operating CF (EUR) Capital Expenditures YoY Change
2024 0.51x €373.99 Million €191.67 Million ▲ +4.6%
2023 0.49x €383.40 Million €187.84 Million ▼ -24.1%
2022 0.65x €386.05 Million €249.33 Million ▼ -91.1%
2021 7.26x €77.83 Million €565.18 Million ▼ -47.1%
2020 13.72x €43.18 Million €592.62 Million ▲ +1023.9%
2019 1.22x €46.01 Million €56.19 Million ▼ -68.5%
2018 3.87x €12.11 Million €46.90 Million ▲ +470.9%
2017 0.68x €27.89 Million €18.92 Million ▲ +95.2%
2016 0.35x €21.12 Million €7.34 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow